Initial pilot programmes will be available to select pharmaceutical and biotechnology partners. Credit: Gorodenkoff / Shutterstock.com. QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery. The move aims to allow pharmaceutical and biotechnology researchers to use AI more effectively by lev...
Initial pilot programmes will be available to select pharmaceutical and biotechnology partners. Credit: Gorodenkoff / Shutterstock.com. QIAGEN’s Digital Insights bioinformatics division is set to integrate NVIDIA’s accelerated computing and the BioNeMo platform to enhance AI-driven drug discovery. The move aims to allow pharmaceutical and biotechnology researchers to use AI more effectively by leveraging enhanced bioinformatics tools and curated knowledge bases. The integration also aims to help them better understand the biology of diseases, identify promising therapeutic targets, and uncover biomarkers to support the development of new medicines. Qiagen and Nvidia are tackling the challenge by applying graph-based AI, using retrieval and reasoning methods over biomedical knowledge graphs. This technology allows researchers to explore evidence across biological systems and supports the creation of agentic, multi-step workflows in the drug discovery process. Qiagen senior vice-president and product portfolio and innovation head Nitin Sood said: “Qiagen Digital Insights has spent more than 25 years building the biomedical knowledge foundation that researchers rely on to interpret complex biology. “Through this collaboration with Nvidia, we can accelerate the impact of that knowledge by combining it with advanced AI to help customers improve critical steps in drug discovery, from target identification to biomarker research and hypothesis generation.” The collaboration targets practical applications throughout the drug discovery process, including identification and validation of targets, repurposing of drugs, biomarker discovery, pathway analysis, and hypothesis generation using multi-omics data. By integrating curated biomedical knowledge, graph-based AI, and accelerated computing, Qiagen seeks to support research teams to transform complex data into well-informed discovery decisions. Initial pilot programmes will be available to select partners in the pharmaceutical...
David Zahn is looking vindicated. He’s been shunning UK bonds for more than a year, when other fund managers were piling in after selloffs. While many will be sitting on hefty losses as the bonds continued to plunge, Zahn is now getting ready to buy as the 30-year yield is within reach of 6%, a level he’s targeted since early 2025. The biggest concern for Franklin Templeton ’s head of European fix...
David Zahn is looking vindicated. He’s been shunning UK bonds for more than a year, when other fund managers were piling in after selloffs. While many will be sitting on hefty losses as the bonds continued to plunge, Zahn is now getting ready to buy as the 30-year yield is within reach of 6%, a level he’s targeted since early 2025. The biggest concern for Franklin Templeton ’s head of European fixed income was that the Labour party would need to spend more after bad results in this month’s elections. “That’s exactly what we’ve seen,” Zahn said in an interview. “It seems clear that everybody wants to spend more money and I just don’t see where the money’s gonna come from unless yields go higher.” The UK’s long term borrowing costs have already hit the highest since 1998 , reaching 5.86% this week, with the latest move spurred by the potential for Manchester mayor Andy Burnham to enter Parliament and challenge Prime Minister Keir Starmer . That’s adding to concerns about the country’s finances and inflation pressures stemming from the Iran war. “Around here is probably a reasonable place to think about buying some yields,” said Zahn. Franklin Templeton oversees $437 billion in fixed income out of its $1.7 trillion of assets under management. For now, he is continuing to stay out of the market after dumping his gilt position in March last year, as he expects yields to rise further as the likely contest to replace Starmer heats up just as the economy sours . “At the moment we have this underlying current of fundamentals, that inflation is higher, oil is higher, and so you see yields rising globally,” Zahn said. “The premium the UK should pay doesn’t necessarily have to change that much, but yet yields can still rise.”
CorVel press release ( CRVL ): Q4 GAAP EPS of $0.61. Revenue of $248.55M (+7.4% Y/Y). Exited the quarter with $233 million of cash, cash equivalents, and no borrowings. The company repurchased $20.1 million of common stock during the quarter. More on CorVel CorVel: Margin-Driven Upside After Growth Reset Historical earnings data for CorVel Financial information for CorVel
CorVel press release ( CRVL ): Q4 GAAP EPS of $0.61. Revenue of $248.55M (+7.4% Y/Y). Exited the quarter with $233 million of cash, cash equivalents, and no borrowings. The company repurchased $20.1 million of common stock during the quarter. More on CorVel CorVel: Margin-Driven Upside After Growth Reset Historical earnings data for CorVel Financial information for CorVel
Key Points Realty Income has a remarkably consistent dividend record. It backs its high-yielding payout with a rock-solid portfolio and financial profile. The REIT still has a long growth runway ahead. 10 stocks we like better than Realty Income › Realty Income (NYSE: O) takes its monthly dividend payments seriously. The real estate investment trust (REIT) also goes by the registered trademarked n...
Key Points Realty Income has a remarkably consistent dividend record. It backs its high-yielding payout with a rock-solid portfolio and financial profile. The REIT still has a long growth runway ahead. 10 stocks we like better than Realty Income › Realty Income (NYSE: O) takes its monthly dividend payments seriously. The real estate investment trust (REIT) also goes by the registered trademarked nickname of "The Monthly Dividend Company." Meanwhile, its stated mission is to "invest in people and places to deliver dependable monthly dividends that increase over time." The REIT has certainly backed that up over the years. It recently declared its 671st consecutive monthly dividend. That's more than half a century of income consistency. Here's why you'll want to buy the REIT if you desire to generate passive income. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » As bankable as it gets Realty Income has everything you'd want in a passive income investment. It pays a monthly dividend, making it a breeze to align your passive income with recurring expenses. The REIT currently offers a high dividend yield. At over 5%, it's several times the yield of the S&P 500, which is currently around 1.1%. That higher yield enables investors to generate more passive income per dollar invested in the REIT. The company backs its high-yielding monthly dividend with a very low-risk business model. Realty Income owns a large, diversified real estate portfolio with over 15,500 retail, industrial, gaming, and other properties across North America and Europe leased to many of the world's leading companies. Long-term net leases underpin its properties. Those leases generate very stable cash flow because tenants cover all property operating costs, including routine maintenance, building insurance, and real estate taxes. Meanw...
Intel stock finally snapped its 5-day winning streak and it’s already back on the charge. The shares were jumping 3.8% in premarket trading after closing 2.4% higher Tuesday to end its five-day losing run. The stock fell 16% over that period and investors were perhaps starting to question whether it would be more than a blip.
Intel stock finally snapped its 5-day winning streak and it’s already back on the charge. The shares were jumping 3.8% in premarket trading after closing 2.4% higher Tuesday to end its five-day losing run. The stock fell 16% over that period and investors were perhaps starting to question whether it would be more than a blip.
(RTTNews) - CorVel Corp. (CRVL) released earnings for its fourth quarter that Increased, from the same period last year The company's bottom line totaled $31.029 million, or $0.61 per share. This compares with $26.419 million, or $0.51 per share, last year. The company's revenue for the period rose 7.4% to $248.548 million from $231.514 million last year. CorVel Corp. earnings at a glance (GAAP) :...
(RTTNews) - CorVel Corp. (CRVL) released earnings for its fourth quarter that Increased, from the same period last year The company's bottom line totaled $31.029 million, or $0.61 per share. This compares with $26.419 million, or $0.51 per share, last year. The company's revenue for the period rose 7.4% to $248.548 million from $231.514 million last year. CorVel Corp. earnings at a glance (GAAP) : -Earnings: $31.029 Mln. vs. $26.419 Mln. last year. -EPS: $0.61 vs. $0.51 last year. -Revenue: $248.548 Mln vs. $231.514 Mln last year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
(RTTNews) - Samsung Electronics Co. Ltd.'s (SSNLF) more than 47,000 workers are likely to begin an 18-day strike on Thursday following the failure of wage negotiations between the company and its labor union. The South Korean government-mediated wage negotiations' core issue remained bonus disputes between the company and the union. The talks involve union's demands over performance-based bonuses ...
(RTTNews) - Samsung Electronics Co. Ltd.'s (SSNLF) more than 47,000 workers are likely to begin an 18-day strike on Thursday following the failure of wage negotiations between the company and its labor union. The South Korean government-mediated wage negotiations' core issue remained bonus disputes between the company and the union. The talks involve union's demands over performance-based bonuses and the company's pay structure, as well as the removal of bonus payout caps and greater transparency. As per reports, the union had agreed to the mediation proposal from South Korea's National Labor Relations Commission, but Samsung rejected it, and asked for more time for negotiations. Meanwhile, Samsung Electronics stated that no decision has been made. According to the firm, accepting the labor union's excessive demands could undermine the fundamental principles of company management. Choi Seung-ho, the spokesperson for the labor union reportedly said, "We express deep regret that the post-mediation process was terminated due to the delay in management's decision-making.' It is expected that that the disrupt in Samsung's memory and AI chip production following the days-long strike would have a massive impact on the company's operating profit and shipments. Amid the developments, there is a speculation of government-forced arbitration as South Korean Finance Minister Koo Yun-cheol and President Lee Jae-Myung reportedly stated that a strike would pose a major risk to national economic growth and exports. In South Korea, Samsung shares closed Wednesday's trading at 276,000.00 won, up 0.18 percent. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
FREDERICA ABAN/iStock via Getty Images Market overview The first quarter of 2026 saw relatively stable performance across most asset classes in January and February but was ultimately defined by the outbreak of war in Iran in March. The S&P 500 Index fell 4.33%, marking its worst quarterly performance since the third quarter of 2022. The Russell 3000 Index, another measure of U.S. equities, fell 3...
FREDERICA ABAN/iStock via Getty Images Market overview The first quarter of 2026 saw relatively stable performance across most asset classes in January and February but was ultimately defined by the outbreak of war in Iran in March. The S&P 500 Index fell 4.33%, marking its worst quarterly performance since the third quarter of 2022. The Russell 3000 Index, another measure of U.S. equities, fell 3.96%. Within the U.S. equity market, large-cap growth stocks were hit particularly hard, with the Russell 1000 Growth Index declining 9.78% as compared to a 2.10% gain for the Russell 1000 Value Index. Indeed, growth-oriented stocks across the capitalization spectrum lagged value-oriented stocks. Mid-cap and small-cap stocks overall outperformed large-cap stocks, as measured by the 1.29% and 0.89% gains of the Russell Midcap Index and Russell 2000 Index, respectively, as compared to the -4.18% return of the Russell 1000 Index. Internationally, the MSCI EAFE Index, measuring developed market equities, fell 1.24%, and the MSCI Emerging Markets Index, measuring emerging markets equities, returned -0.17%, each in U.S. dollar terms, as U.S. dollar appreciation weighed on dollar-based returns from overseas markets, offsetting otherwise healthy equity performance abroad. Fixed-income market returns were muted across the quality spectrum, as inflation expectations shifted upward with the U.S.-Iran war. The U.S. Federal Reserve held interest rates steady, and the outlook for cuts was called into question. The Bloomberg U.S. Aggregate Bond Index returned -0.05%. U.S. Treasuries, per the Bloomberg Treasury Index, returned -0.04%, Investment-grade corporate bonds, per the Bloomberg U.S. Corporate Bond Index, returned -0.54%, and high-yield corporate bonds, per the Bloomberg U.S. Corporate High Yield Index, returned -0.50%. Securitized assets, per the Bloomberg U.S. Securitized Index, rose 0.40%. Emerging markets debt returned -1.35%, as measured by the Bloomberg Emerging Markets USD Ag...
China scaled back government spending at its fastest pace in six months in April, a move that contributed to an unexpected slowdown in the economy across the board. A broad measure of public expenditure fell 7.3% from a year ago, accelerating from the 2.5% decrease in March to mark its sharpest decline since October, according to Bloomberg calculations based on Ministry of Finance data released We...
China scaled back government spending at its fastest pace in six months in April, a move that contributed to an unexpected slowdown in the economy across the board. A broad measure of public expenditure fell 7.3% from a year ago, accelerating from the 2.5% decrease in March to mark its sharpest decline since October, according to Bloomberg calculations based on Ministry of Finance data released Wednesday. By contrast, broad fiscal revenue rose 2%. The data helps explain a surprising contraction in fixed-asset investment that China recorded in April, which followed a rebound earlier this year. Combined with sluggish consumer spending, the investment downturn outweighed booming exports, dragging down overall economic activity. Economists have pointed to several reasons for the fiscal pullback. Solid economic growth in the first quarter may have reduced the impetus for authorities to step up spending. Others noted a potential funding gap in April, as some construction projects were moved from late 2025 to early 2026 while new projects had yet to receive approval. Officials may also have faced pressure to repay arrears to companies. Infrastructure-related expenditure under China’s main budget plunged 17.7% in April from a year earlier, worsening from the 8.5% drop in March, according to Bloomberg calculations. China will likely increase infrastructure spending to shore up growth. Some economists estimate that China’s economic expansion slowed to roughly 4% in April, tracking below the government’s official full-year target of 4.5% to 5%. In April, the Communist Party’s decision-making Politburo pledged to accelerate the construction of infrastructure networks spanning water, electricity, computing power, telecommunications, urban underground pipes and logistics. Investment in those projects could exceed 7 trillion yuan ($1 trillion) this year, according to Sinolink Securities’ estimate .
Belite Bio press release ( BLTE ): Q1 Non-GAAP EPS of -$0.34 beats by $0.30 . Cash and Cash Equivalents: As of March 31, 2026, the Company had $276.4 million in cash and cash equivalents, compared with $352.9 million on December 31, 2025. Investments: As of March 31, 2026, the Company had $522.2 million in U.S. treasury bills and U.S. treasury notes, compared to $419.7 million as of December 31, 2...
Belite Bio press release ( BLTE ): Q1 Non-GAAP EPS of -$0.34 beats by $0.30 . Cash and Cash Equivalents: As of March 31, 2026, the Company had $276.4 million in cash and cash equivalents, compared with $352.9 million on December 31, 2025. Investments: As of March 31, 2026, the Company had $522.2 million in U.S. treasury bills and U.S. treasury notes, compared to $419.7 million as of December 31, 2025. More on Belite Bio Belite Bio, Inc (BLTE) Presents at Bank of America Global Healthcare Conference 2026 Transcript Belite Bio, Inc (BLTE) Presents at FFB Retinal Therapeutics Innovation Summit - Slideshow Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor Conference - Slideshow Belite Bio targets Q2 2026 NDA submission and $200M–$250M commercialization spend for Stargardt therapy while cash reserves surge Seeking Alpha’s Quant Rating on Belite Bio